Press Releases

 
Press Releases
Date Title and Summary View
Jan 7, 2016 SALT LAKE CITY, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced tha...
Jan 4, 2016 SALT LAKE CITY, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 34th annual J.P. Morgan Healthcare Conference at 9:30 a.m. PST (12:30 pm EST) on January 11, 2016, at the Westin St. Francis in S...
Dec 10, 2015 SALT LAKE CITY, Dec. 10, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data will be presented demonstrating the role of the myChoice HRD companion diagnostic in identifying patients with breast cancer who are likely to respond to a platinum-contain...
Dec 9, 2015 SALT LAKE CITY, Dec. 9, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will highlight three scientific presentations related to its myRisk Hereditary Cancer test at the 2015 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. Data include r...
Dec 1, 2015 SALT LAKE CITY, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent No. 9,200,324. The patent, which is expected to expire in 2031, provides intellectual property protection fo...
Nov 17, 2015 New Data on the myChoice® HRD and myRisk™ Hereditary Cancer Tests Will be Highlighted SALT LAKE CITY, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that it will present eight posters at the 2015 San Antonio Breast Cancer Symposium (S...
Nov 16, 2015 SALT LAKE CITY, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that its DiscoveryMAP® platform successfully identified combinations of 15 protein biomarkers associated with cardiovascular (CV) events or death in people with pre-diabetes or early type 2 diabetes, a...
Nov 7, 2015 SALT LAKE CITY, Nov. 7, 2015 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra DA to predict treatment response in patients with rheumatoid arthritis (RA) are being presented at the American College of Rheumatology/Association of Rheumatolog...
Nov 3, 2015 Total Revenues of $183.5 Million Adjusted Diluted EPS of $0.41 and Diluted EPS of $0.37 Myriad Completes Conversion of Targeted Physicians to myRisk™ Hereditary CancerCompany Maintains Fiscal Year 2016 Financial Guidance and provides Fiscal Second-Quarter 2016 Financial Guidance SALT LAKE CITY, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Myriad Gene...
Oct 28, 2015 SALT LAKE CITY, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 24th Annual Credit Suisse Healthcare Conference at 5:00 pm EST on November 11, 2015, at the Phoenician Resort in Phoenix, Arizona. The presentation will be ...
Page: FirstPrevious
4
... NextLast
= add release to Briefcase